HEADER TRANSPORT PROTEIN 22-FEB-18 6FTP TITLE CRYSTAL FORM 1 OF ALPHA1-ANTICHYMOTRYPSIN VARIANT DBS-II-ALLO: AN TITLE 2 ALLOSTERICALLY MODULATED DRUG-BINDING SERPIN FOR DOXORUBICIN COMPND MOL_ID: 1; COMPND 2 MOLECULE: ALPHA-1-ANTICHYMOTRYPSIN; COMPND 3 CHAIN: A; COMPND 4 SYNONYM: ACT,CELL GROWTH-INHIBITING GENE 24/25 PROTEIN,SERPIN A3; COMPND 5 ENGINEERED: YES; COMPND 6 MUTATION: YES; COMPND 7 OTHER_DETAILS: ALL N-TERMINAL RESIDUES THAT ARE PRESENT IN THE SAMPLE COMPND 8 SEQUENCE BUT NOT IN THE PDB FILE COULD NOT BE MODELLED DUE TO MISSING COMPND 9 ELECTRON DENSITY. THE PROTEIN IS SPLITTED INTO CHAIN A AND CHAIN B, COMPND 10 AS IT BELONGS TO THE SERINE PROTEINASE INHIBITOR (SERPIN) FAMILY AND COMPND 11 IS PROTEOLYTICALLY CLEAVED C-TERMINAL OF GLN360. THE RESIDUES GLN360 COMPND 12 AND ARG376, WHICH IS THE FIRST RESIDUE VISIBLE IN THE ELECTRON COMPND 13 DENSITY, ARE 70 ANGSTROM APART BECAUSE OF THE SERPIN-TYPICAL COMPND 14 CONFORMATIONAL CHANGE UPON PROTEOLYTICAL CLEAVAGE. THE SEQUENCE COMPND 15 FOLLOWING THE P1-P1' SCISSILE BOND, NAMELY RESIDUES GPL..KQA, ARE COMPND 16 PART OF CHAIN B.; COMPND 17 MOL_ID: 2; COMPND 18 MOLECULE: ALPHA-1-ANTICHYMOTRYPSIN; COMPND 19 CHAIN: B; COMPND 20 SYNONYM: ACT,CELL GROWTH-INHIBITING GENE 24/25 PROTEIN,SERPIN A3; COMPND 21 ENGINEERED: YES; COMPND 22 MUTATION: YES; COMPND 23 OTHER_DETAILS: THE PROTEIN IS SPLITTED INTO CHAIN A AND CHAIN B, AS COMPND 24 IT BELONGS TO THE SERINE PROTEINASE INHIBITOR (SERPIN) FAMILY AND IS COMPND 25 PROTEOLYTICALLY CLEAVED C-TERMINAL OF GLN360. THE RESIDUES GLN360 AND COMPND 26 ARG376, WHICH IS THE FIRST RESIDUE VISIBLE IN THE ELECTRON DENSITY, COMPND 27 ARE 70 ANGSTROM APART BECAUSE OF THE SERPIN-TYPICAL CONFORMATIONAL COMPND 28 CHANGE UPON PROTEOLYTICAL CLEAVAGE. THE SEQUENCE FOLLOWING THE P1-P1' COMPND 29 SCISSILE BOND, NAMELY RESIDUES GPL..KQA, ARE PART OF CHAIN B. THE COMPND 30 RESIDUES 361-366 (GPLVET) ARE MISSING IN THE PDB FILE BECAUSE OF COMPND 31 MISSING ELECTRON DENSITY. SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 GENE: SERPINA3, AACT, GIG24, GIG25; SOURCE 6 EXPRESSION_SYSTEM: ESCHERICHIA COLI BL21(DE3); SOURCE 7 EXPRESSION_SYSTEM_TAXID: 469008; SOURCE 8 EXPRESSION_SYSTEM_VARIANT: STAR; SOURCE 9 MOL_ID: 2; SOURCE 10 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 11 ORGANISM_COMMON: HUMAN; SOURCE 12 ORGANISM_TAXID: 9606; SOURCE 13 GENE: SERPINA3, AACT, GIG24, GIG25; SOURCE 14 EXPRESSION_SYSTEM: ESCHERICHIA COLI BL21(DE3); SOURCE 15 EXPRESSION_SYSTEM_TAXID: 469008; SOURCE 16 EXPRESSION_SYSTEM_VARIANT: STAR KEYWDS SERPIN, ALPHA1-ANTICHYMOTRYPSIN, DOXORUBICIN-BINDING PROTEIN, KEYWDS 2 ALLOSTERICALLY TRIGGERED DRUG RELEASE, TRANSPORT PROTEIN EXPDTA X-RAY DIFFRACTION AUTHOR K.SCHMIDT,Y.A.MULLER REVDAT 3 17-JAN-24 6FTP 1 AUTHOR REVDAT 2 06-JUN-18 6FTP 1 JRNL REVDAT 1 23-MAY-18 6FTP 0 JRNL AUTH K.SCHMIDT,B.R.GARDILL,A.KERN,P.KIRCHWEGER,M.BORSCH, JRNL AUTH 2 Y.A.MULLER JRNL TITL DESIGN OF AN ALLOSTERICALLY MODULATED DOXYCYCLINE AND JRNL TITL 2 DOXORUBICIN DRUG-BINDING PROTEIN. JRNL REF PROC. NATL. ACAD. SCI. V. 115 5744 2018 JRNL REF 2 U.S.A. JRNL REFN ESSN 1091-6490 JRNL PMID 29760101 JRNL DOI 10.1073/PNAS.1716666115 REMARK 2 REMARK 2 RESOLUTION. 1.80 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : PHENIX (1.13_2998: ???) REMARK 3 AUTHORS : PAUL ADAMS,PAVEL AFONINE,VINCENT CHEN,IAN REMARK 3 : DAVIS,KRESHNA GOPAL,RALF GROSSE-KUNSTLEVE, REMARK 3 : LI-WEI HUNG,ROBERT IMMORMINO,TOM IOERGER, REMARK 3 : AIRLIE MCCOY,ERIK MCKEE,NIGEL MORIARTY, REMARK 3 : REETAL PAI,RANDY READ,JANE RICHARDSON, REMARK 3 : DAVID RICHARDSON,TOD ROMO,JIM SACCHETTINI, REMARK 3 : NICHOLAS SAUTER,JACOB SMITH,LAURENT REMARK 3 : STORONI,TOM TERWILLIGER,PETER ZWART REMARK 3 REMARK 3 REFINEMENT TARGET : NULL REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 1.80 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 42.12 REMARK 3 MIN(FOBS/SIGMA_FOBS) : 1.370 REMARK 3 COMPLETENESS FOR RANGE (%) : 99.9 REMARK 3 NUMBER OF REFLECTIONS : 37567 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 R VALUE (WORKING + TEST SET) : 0.197 REMARK 3 R VALUE (WORKING SET) : 0.195 REMARK 3 FREE R VALUE : 0.221 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 5.000 REMARK 3 FREE R VALUE TEST SET COUNT : 1877 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT (IN BINS). REMARK 3 BIN RESOLUTION RANGE COMPL. NWORK NFREE RWORK RFREE REMARK 3 1 42.1315 - 4.2297 1.00 2908 153 0.1723 0.1793 REMARK 3 2 4.2297 - 3.3577 1.00 2800 147 0.1700 0.1762 REMARK 3 3 3.3577 - 2.9334 1.00 2753 145 0.1945 0.2098 REMARK 3 4 2.9334 - 2.6652 1.00 2757 145 0.2054 0.2322 REMARK 3 5 2.6652 - 2.4742 1.00 2727 143 0.2095 0.2715 REMARK 3 6 2.4742 - 2.3284 1.00 2756 146 0.2101 0.2238 REMARK 3 7 2.3284 - 2.2118 1.00 2692 140 0.2050 0.2780 REMARK 3 8 2.2118 - 2.1155 1.00 2738 144 0.2167 0.2959 REMARK 3 9 2.1155 - 2.0341 1.00 2745 145 0.2174 0.2931 REMARK 3 10 2.0341 - 1.9639 1.00 2708 142 0.2181 0.2517 REMARK 3 11 1.9639 - 1.9025 1.00 2715 143 0.2307 0.2707 REMARK 3 12 1.9025 - 1.8481 1.00 2694 142 0.2568 0.2915 REMARK 3 13 1.8481 - 1.7994 1.00 2697 142 0.2994 0.3331 REMARK 3 REMARK 3 BULK SOLVENT MODELLING. REMARK 3 METHOD USED : NULL REMARK 3 SOLVENT RADIUS : 1.11 REMARK 3 SHRINKAGE RADIUS : 0.90 REMARK 3 K_SOL : NULL REMARK 3 B_SOL : NULL REMARK 3 REMARK 3 ERROR ESTIMATES. REMARK 3 COORDINATE ERROR (MAXIMUM-LIKELIHOOD BASED) : 0.220 REMARK 3 PHASE ERROR (DEGREES, MAXIMUM-LIKELIHOOD BASED) : 23.340 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : NULL REMARK 3 MEAN B VALUE (OVERALL, A**2) : NULL REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : NULL REMARK 3 B22 (A**2) : NULL REMARK 3 B33 (A**2) : NULL REMARK 3 B12 (A**2) : NULL REMARK 3 B13 (A**2) : NULL REMARK 3 B23 (A**2) : NULL REMARK 3 REMARK 3 TWINNING INFORMATION. REMARK 3 FRACTION: NULL REMARK 3 OPERATOR: NULL REMARK 3 REMARK 3 DEVIATIONS FROM IDEAL VALUES. REMARK 3 RMSD COUNT REMARK 3 BOND : 0.010 3246 REMARK 3 ANGLE : 0.939 4403 REMARK 3 CHIRALITY : 0.229 506 REMARK 3 PLANARITY : 0.006 556 REMARK 3 DIHEDRAL : 19.446 1186 REMARK 3 REMARK 3 TLS DETAILS REMARK 3 NUMBER OF TLS GROUPS : NULL REMARK 3 REMARK 3 NCS DETAILS REMARK 3 NUMBER OF NCS GROUPS : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 6FTP COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY PDBE ON 22-FEB-18. REMARK 100 THE DEPOSITION ID IS D_1200008912. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 12-MAY-17 REMARK 200 TEMPERATURE (KELVIN) : 100 REMARK 200 PH : NULL REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : BESSY REMARK 200 BEAMLINE : 14.2 REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 0.9184 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : PIXEL REMARK 200 DETECTOR MANUFACTURER : DECTRIS PILATUS 2M REMARK 200 INTENSITY-INTEGRATION SOFTWARE : XDS REMARK 200 DATA SCALING SOFTWARE : XSCALE REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 37572 REMARK 200 RESOLUTION RANGE HIGH (A) : 1.800 REMARK 200 RESOLUTION RANGE LOW (A) : 42.120 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : NULL REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 99.9 REMARK 200 DATA REDUNDANCY : 9.900 REMARK 200 R MERGE (I) : NULL REMARK 200 R SYM (I) : 0.05800 REMARK 200 <I/SIGMA(I)> FOR THE DATA SET : 25.3100 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 1.80 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 1.91 REMARK 200 COMPLETENESS FOR SHELL (%) : 99.8 REMARK 200 DATA REDUNDANCY IN SHELL : 10.10 REMARK 200 R MERGE FOR SHELL (I) : NULL REMARK 200 R SYM FOR SHELL (I) : 0.83400 REMARK 200 <I/SIGMA(I)> FOR SHELL : 2.760 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: PHASER REMARK 200 STARTING MODEL: 5OM8 REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 42.44 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.14 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: 0.2 M SODIUM THIOCYANATE, 20 % W/V PEG REMARK 280 3350, VAPOR DIFFUSION, SITTING DROP, TEMPERATURE 293K REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 31 2 1 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -Y,X-Y,Z+1/3 REMARK 290 3555 -X+Y,-X,Z+2/3 REMARK 290 4555 Y,X,-Z REMARK 290 5555 X-Y,-Y,-Z+2/3 REMARK 290 6555 -X,-X+Y,-Z+1/3 REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -0.500000 -0.866025 0.000000 0.00000 REMARK 290 SMTRY2 2 0.866025 -0.500000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 32.48100 REMARK 290 SMTRY1 3 -0.500000 0.866025 0.000000 0.00000 REMARK 290 SMTRY2 3 -0.866025 -0.500000 0.000000 0.00000 REMARK 290 SMTRY3 3 0.000000 0.000000 1.000000 64.96200 REMARK 290 SMTRY1 4 -0.500000 0.866025 0.000000 0.00000 REMARK 290 SMTRY2 4 0.866025 0.500000 0.000000 0.00000 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 SMTRY1 5 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 5 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 5 0.000000 0.000000 -1.000000 64.96200 REMARK 290 SMTRY1 6 -0.500000 -0.866025 0.000000 0.00000 REMARK 290 SMTRY2 6 -0.866025 0.500000 0.000000 0.00000 REMARK 290 SMTRY3 6 0.000000 0.000000 -1.000000 32.48100 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: DIMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: DIMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 TOTAL BURIED SURFACE AREA: 6110 ANGSTROM**2 REMARK 350 SURFACE AREA OF THE COMPLEX: 15370 ANGSTROM**2 REMARK 350 CHANGE IN SOLVENT FREE ENERGY: -23.0 KCAL/MOL REMARK 350 APPLY THE FOLLOWING TO CHAINS: A, B REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 375 REMARK 375 SPECIAL POSITION REMARK 375 THE FOLLOWING ATOMS ARE FOUND TO BE WITHIN 0.15 ANGSTROMS REMARK 375 OF A SYMMETRY RELATED ATOM AND ARE ASSUMED TO BE ON SPECIAL REMARK 375 POSITIONS. REMARK 375 REMARK 375 ATOM RES CSSEQI REMARK 375 HOH A 527 LIES ON A SPECIAL POSITION. REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 MET A -8 REMARK 465 LYS A -7 REMARK 465 HIS A -6 REMARK 465 HIS A -5 REMARK 465 HIS A -4 REMARK 465 HIS A -3 REMARK 465 HIS A -2 REMARK 465 HIS A -1 REMARK 465 MET A 0 REMARK 465 LYS A 1 REMARK 465 GLN A 2 REMARK 465 ASN A 3 REMARK 465 SER A 4 REMARK 465 PRO A 5 REMARK 465 LEU A 6 REMARK 465 ASP A 7 REMARK 465 GLU A 8 REMARK 465 GLU A 9 REMARK 465 ASN A 10 REMARK 465 LEU A 11 REMARK 465 THR A 12 REMARK 465 GLN A 13 REMARK 465 GLU A 14 REMARK 465 ASN A 15 REMARK 465 GLN A 16 REMARK 465 ASP A 17 REMARK 465 ARG A 18 REMARK 465 GLY A 19 REMARK 465 THR A 20 REMARK 465 HIS A 21 REMARK 465 VAL A 22 REMARK 465 ASP A 23 REMARK 465 ARG A 24 REMARK 465 GLY A 25 REMARK 465 GLY B 361 REMARK 465 PRO B 362 REMARK 465 LEU B 363 REMARK 465 VAL B 364 REMARK 465 GLU B 365 REMARK 465 THR B 366 REMARK 470 REMARK 470 MISSING ATOM REMARK 470 THE FOLLOWING RESIDUES HAVE MISSING ATOMS (M=MODEL NUMBER; REMARK 470 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; REMARK 470 I=INSERTION CODE): REMARK 470 M RES CSSEQI ATOMS REMARK 470 ARG B 367 CG CD NE CZ NH1 NH2 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 ALA A 45 86.49 -162.76 REMARK 500 ASN A 70 -137.65 60.49 REMARK 500 HIS A 225 79.95 49.17 REMARK 500 REMARK 500 REMARK: NULL REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue EDO A 401 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue EDO A 402 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC3 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue EDO A 403 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC4 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue DM2 B 501 REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 5OM8 RELATED DB: PDB REMARK 900 5OM8 CONTAINS THE SAME PROTEIN WITHOUT ANY LIGAND BOUND DBREF 6FTP A 3 360 UNP P01011 AACT_HUMAN 26 383 DBREF 6FTP B 363 400 UNP P01011 AACT_HUMAN 386 423 SEQADV 6FTP MET A -8 UNP P01011 INITIATING METHIONINE SEQADV 6FTP LYS A -7 UNP P01011 EXPRESSION TAG SEQADV 6FTP HIS A -6 UNP P01011 EXPRESSION TAG SEQADV 6FTP HIS A -5 UNP P01011 EXPRESSION TAG SEQADV 6FTP HIS A -4 UNP P01011 EXPRESSION TAG SEQADV 6FTP HIS A -3 UNP P01011 EXPRESSION TAG SEQADV 6FTP HIS A -2 UNP P01011 EXPRESSION TAG SEQADV 6FTP HIS A -1 UNP P01011 EXPRESSION TAG SEQADV 6FTP MET A 0 UNP P01011 EXPRESSION TAG SEQADV 6FTP LYS A 1 UNP P01011 EXPRESSION TAG SEQADV 6FTP GLN A 2 UNP P01011 EXPRESSION TAG SEQADV 6FTP ARG A 24 UNP P01011 LEU 47 ENGINEERED MUTATION SEQADV 6FTP PHE A 194 UNP P01011 TRP 217 ENGINEERED MUTATION SEQADV 6FTP TYR A 215 UNP P01011 TRP 238 ENGINEERED MUTATION SEQADV 6FTP GLN A 242 UNP P01011 GLU 265 ENGINEERED MUTATION SEQADV 6FTP ASN A 244 UNP P01011 LYS 267 ENGINEERED MUTATION SEQADV 6FTP SER A 269 UNP P01011 LEU 292 ENGINEERED MUTATION SEQADV 6FTP GLN A 270 UNP P01011 PRO 293 ENGINEERED MUTATION SEQADV 6FTP SER A 274 UNP P01011 LYS 297 ENGINEERED MUTATION SEQADV 6FTP PHE A 276 UNP P01011 TRP 299 ENGINEERED MUTATION SEQADV 6FTP PHE A 277 UNP P01011 ARG 300 ENGINEERED MUTATION SEQADV 6FTP GLU A 278 UNP P01011 ASP 301 ENGINEERED MUTATION SEQADV 6FTP ARG A 349 UNP P01011 ALA 372 ENGINEERED MUTATION SEQADV 6FTP LEU A 355 UNP P01011 VAL 378 ENGINEERED MUTATION SEQADV 6FTP GLU A 356 UNP P01011 LYS 379 ENGINEERED MUTATION SEQADV 6FTP VAL A 357 UNP P01011 ILE 380 ENGINEERED MUTATION SEQADV 6FTP LEU A 358 UNP P01011 THR 381 ENGINEERED MUTATION SEQADV 6FTP PHE A 359 UNP P01011 LEU 382 ENGINEERED MUTATION SEQADV 6FTP GLN A 360 UNP P01011 LEU 383 ENGINEERED MUTATION SEQADV 6FTP GLY B 361 UNP P01011 ENGINEERED MUTATION SEQADV 6FTP PRO B 362 UNP P01011 ENGINEERED MUTATION SEQADV 6FTP ASP B 382 UNP P01011 PRO 405 ENGINEERED MUTATION SEQADV 6FTP ASN B 383 UNP P01011 THR 406 ENGINEERED MUTATION SEQADV 6FTP PHE B 384 UNP P01011 ASP 407 ENGINEERED MUTATION SEQADV 6FTP TRP B 386 UNP P01011 GLN 409 ENGINEERED MUTATION SEQADV 6FTP SER B 387 UNP P01011 ASN 410 ENGINEERED MUTATION SEQRES 1 A 369 MET LYS HIS HIS HIS HIS HIS HIS MET LYS GLN ASN SER SEQRES 2 A 369 PRO LEU ASP GLU GLU ASN LEU THR GLN GLU ASN GLN ASP SEQRES 3 A 369 ARG GLY THR HIS VAL ASP ARG GLY LEU ALA SER ALA ASN SEQRES 4 A 369 VAL ASP PHE ALA PHE SER LEU TYR LYS GLN LEU VAL LEU SEQRES 5 A 369 LYS ALA PRO ASP LYS ASN VAL ILE PHE SER PRO LEU SER SEQRES 6 A 369 ILE SER THR ALA LEU ALA PHE LEU SER LEU GLY ALA HIS SEQRES 7 A 369 ASN THR THR LEU THR GLU ILE LEU LYS GLY LEU LYS PHE SEQRES 8 A 369 ASN LEU THR GLU THR SER GLU ALA GLU ILE HIS GLN SER SEQRES 9 A 369 PHE GLN HIS LEU LEU ARG THR LEU ASN GLN SER SER ASP SEQRES 10 A 369 GLU LEU GLN LEU SER MET GLY ASN ALA MET PHE VAL LYS SEQRES 11 A 369 GLU GLN LEU SER LEU LEU ASP ARG PHE THR GLU ASP ALA SEQRES 12 A 369 LYS ARG LEU TYR GLY SER GLU ALA PHE ALA THR ASP PHE SEQRES 13 A 369 GLN ASP SER ALA ALA ALA LYS LYS LEU ILE ASN ASP TYR SEQRES 14 A 369 VAL LYS ASN GLY THR ARG GLY LYS ILE THR ASP LEU ILE SEQRES 15 A 369 LYS ASP LEU ASP SER GLN THR MET MET VAL LEU VAL ASN SEQRES 16 A 369 TYR ILE PHE PHE LYS ALA LYS PHE GLU MET PRO PHE ASP SEQRES 17 A 369 PRO GLN ASP THR HIS GLN SER ARG PHE TYR LEU SER LYS SEQRES 18 A 369 LYS LYS TYR VAL MET VAL PRO MET MET SER LEU HIS HIS SEQRES 19 A 369 LEU THR ILE PRO TYR PHE ARG ASP GLU GLU LEU SER CYS SEQRES 20 A 369 THR VAL VAL GLN LEU ASN TYR THR GLY ASN ALA SER ALA SEQRES 21 A 369 LEU PHE ILE LEU PRO ASP GLN ASP LYS MET GLU GLU VAL SEQRES 22 A 369 GLU ALA MET LEU SER GLN GLU THR LEU SER ARG PHE PHE SEQRES 23 A 369 GLU SER LEU GLU PHE ARG GLU ILE GLY GLU LEU TYR LEU SEQRES 24 A 369 PRO LYS PHE SER ILE SER ARG ASP TYR ASN LEU ASN ASP SEQRES 25 A 369 ILE LEU LEU GLN LEU GLY ILE GLU GLU ALA PHE THR SER SEQRES 26 A 369 LYS ALA ASP LEU SER GLY ILE THR GLY ALA ARG ASN LEU SEQRES 27 A 369 ALA VAL SER GLN VAL VAL HIS LYS ALA VAL LEU ASP VAL SEQRES 28 A 369 PHE GLU GLU GLY THR GLU ARG SER ALA ALA THR ALA LEU SEQRES 29 A 369 GLU VAL LEU PHE GLN SEQRES 1 B 40 GLY PRO LEU VAL GLU THR ARG THR ILE VAL ARG PHE ASN SEQRES 2 B 40 ARG PRO PHE LEU MET ILE ILE VAL ASP ASN PHE THR TRP SEQRES 3 B 40 SER ILE PHE PHE MET SER LYS VAL THR ASN PRO LYS GLN SEQRES 4 B 40 ALA HET EDO A 401 4 HET EDO A 402 4 HET EDO A 403 4 HET DM2 B 501 39 HETNAM EDO 1,2-ETHANEDIOL HETNAM DM2 DOXORUBICIN HETSYN EDO ETHYLENE GLYCOL HETSYN DM2 ADRIAMYCIN FORMUL 3 EDO 3(C2 H6 O2) FORMUL 6 DM2 C27 H29 N O11 FORMUL 7 HOH *197(H2 O) HELIX 1 AA1 LEU A 26 ALA A 45 1 20 HELIX 2 AA2 SER A 53 LEU A 66 1 14 HELIX 3 AA3 HIS A 69 LEU A 80 1 12 HELIX 4 AA4 SER A 88 LEU A 103 1 16 HELIX 5 AA5 LEU A 127 GLY A 139 1 13 HELIX 6 AA6 ASP A 149 THR A 165 1 17 HELIX 7 AA7 ASP A 199 THR A 203 5 5 HELIX 8 AA8 LYS A 260 LEU A 268 1 9 HELIX 9 AA9 SER A 269 LEU A 280 1 12 HELIX 10 AB1 LEU A 301 LEU A 308 1 8 HELIX 11 AB2 GLU A 311 THR A 315 5 5 HELIX 12 AB3 LEU A 320 GLY A 325 1 6 SHEET 1 AA1 7 VAL A 50 PHE A 52 0 SHEET 2 AA1 7 ILE B 388 VAL B 394 -1 O LYS B 393 N VAL A 50 SHEET 3 AA1 7 PHE B 376 ASP B 382 -1 N PHE B 376 O VAL B 394 SHEET 4 AA1 7 ALA A 249 PRO A 256 -1 N LEU A 252 O ILE B 379 SHEET 5 AA1 7 CYS A 238 LEU A 243 -1 N THR A 239 O LEU A 255 SHEET 6 AA1 7 TYR A 215 ASP A 233 -1 N PHE A 231 O VAL A 240 SHEET 7 AA1 7 HIS A 204 TYR A 209 -1 N PHE A 208 O VAL A 216 SHEET 1 AA2 8 VAL A 50 PHE A 52 0 SHEET 2 AA2 8 ILE B 388 VAL B 394 -1 O LYS B 393 N VAL A 50 SHEET 3 AA2 8 PHE B 376 ASP B 382 -1 N PHE B 376 O VAL B 394 SHEET 4 AA2 8 ALA A 249 PRO A 256 -1 N LEU A 252 O ILE B 379 SHEET 5 AA2 8 CYS A 238 LEU A 243 -1 N THR A 239 O LEU A 255 SHEET 6 AA2 8 TYR A 215 ASP A 233 -1 N PHE A 231 O VAL A 240 SHEET 7 AA2 8 GLU A 281 PRO A 291 -1 O ILE A 285 N LEU A 226 SHEET 8 AA2 8 ILE B 369 ARG B 371 1 O VAL B 370 N TYR A 289 SHEET 1 AA3 3 GLN A 105 SER A 106 0 SHEET 2 AA3 3 LEU A 110 LYS A 121 -1 O LEU A 112 N GLN A 105 SHEET 3 AA3 3 GLU A 141 THR A 145 1 O PHE A 143 N VAL A 120 SHEET 1 AA4 6 GLN A 105 SER A 106 0 SHEET 2 AA4 6 LEU A 110 LYS A 121 -1 O LEU A 112 N GLN A 105 SHEET 3 AA4 6 THR A 180 LYS A 193 -1 O LYS A 191 N GLN A 111 SHEET 4 AA4 6 GLY A 346 PHE A 359 -1 O ARG A 349 N PHE A 190 SHEET 5 AA4 6 LEU A 329 VAL A 342 -1 N GLN A 333 O GLU A 356 SHEET 6 AA4 6 PHE A 293 ASN A 300 -1 N PHE A 293 O VAL A 342 SITE 1 AC1 5 LEU A 41 TYR A 299 ASN A 300 ILE A 304 SITE 2 AC1 5 HOH A 582 SITE 1 AC2 5 PHE A 194 GLU A 195 MET A 196 LEU A 243 SITE 2 AC2 5 ASN A 244 SITE 1 AC3 8 PHE A 190 ALA A 192 ASN A 244 ALA A 249 SITE 2 AC3 8 SER A 250 ALA A 251 THR A 347 HOH A 515 SITE 1 AC4 10 GLN A 242 TYR A 245 LEU A 273 SER A 274 SITE 2 AC4 10 PHE A 277 GLU A 278 LEU A 280 VAL B 381 SITE 3 AC4 10 ASN B 383 TRP B 386 CRYST1 84.240 84.240 97.443 90.00 90.00 120.00 P 31 2 1 6 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.011871 0.006854 0.000000 0.00000 SCALE2 0.000000 0.013707 0.000000 0.00000 SCALE3 0.000000 0.000000 0.010262 0.00000